19.66
0.17 (0.87%)
| Penutupan Terdahulu | 19.49 |
| Buka | 19.42 |
| Jumlah Dagangan | 520,164 |
| Purata Dagangan (3B) | 313,911 |
| Modal Pasaran | 797,585,408 |
| Harga / Buku (P/B) | 3.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -3.76 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 14.34 |
| Aliran Tunai Operasi (OCF TTM) | -119.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.54 M |
| Pulangan Atas Aset (ROA TTM) | -23.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ArriVent BioPharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 85.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Hidden Lake Asset Management Lp | 30 Jun 2025 | 606,851 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 43.00 (Truist Securities, 118.72%) | Beli |
| Median | 37.00 (88.20%) | |
| Rendah | 31.00 (Citigroup, 57.68%) | Beli |
| Purata | 37.00 (88.20%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 21.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 25 Nov 2025 | 43.00 (118.72%) | Beli | 22.78 |
| Citigroup | 11 Nov 2025 | 31.00 (57.68%) | Beli | 19.38 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2025 | Pengumuman | ArriVent BioPharma Reports Third Quarter 2025 Financial Results |
| 22 Sep 2025 | Pengumuman | ArriVent Appoints Brent S. Rice as Chief Commercial Officer |
| 09 Sep 2025 | Pengumuman | Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |